There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Selecta Biosciences (NASDAQ: SELB), Blueprint Medicines (NASDAQ: BPMC) and Horizon Pharma Inc (NASDAQ: HZNP) with bullish sentiments.
Selecta Biosciences (NASDAQ: SELB)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Selecta Biosciences (NASDAQ: SELB), with a price target of $40. The company’s shares opened today at $11.97.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 19.5% and a 48.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Atara Biotherapeutics, and Gemphire Therapeutics.
Selecta Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $35.
See today’s analyst top recommended stocks >>
Blueprint Medicines (NASDAQ: BPMC)
Cowen & Co. analyst Eric Schmidt maintained a Buy rating on Blueprint Medicines (NASDAQ: BPMC) today. The company’s shares opened today at $74.43.
According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 45.1% and a 64.6% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Blueprint Medicines is Strong Buy and the average price target is $105.25, representing a 41.4% upside.
In a report issued on June 2, BTIG also maintained a Buy rating on the stock with a $107 price target.
Horizon Pharma Inc (NASDAQ: HZNP)
Mizuho Securities analyst Irina Rivkind Koffler maintained a Buy rating on Horizon Pharma Inc (NASDAQ: HZNP) today and set a price target of $18. The company’s shares opened today at $17.68, close to its 52-week high of $18.11.
Rivkind Koffler wrote:
“We valued HZNP using discounted cash flow analysis, and we utilized a weighted average cost of capital of 12% and a 2% terminal growth rate because we credit the company for Teprotumumab and M&A. This analysis generated a valuation of $18 per share and supports our Buy rating.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 13.7% and a 48.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Pacira Pharmaceuticals, and Adamas Pharmaceuticals.
Horizon Pharma Inc has an analyst consensus of Moderate Buy, with a price target consensus of $17.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
